Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- CMS Approves New Technology Add-on Payment for Reflow Medical’s Spur® Peripheral Retrievable Stent SystemSAN CLEMENTE, Calif., September 01, 2026--Reflow Medical, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted the Spur Peripheral Retrievable Stent System a New Technology Add-on Payment (NTAP), providing additional reimbursement for eligible Fee-for-Service Medicare inpatient cases beginning October 1, 2026.
- Nicklaus Children's HospitalFather-to-daughter bone marrow transplant gives daughter a second chance at lifeFirst case of its kind at Nicklaus Children's Hospital and among only a few in the — Nicklaus Children's Hospital Helen & Jacob Shaham Cancer & Blood Disorders Institute has successfully accomplished a bone marrow transplant on a 2-year-old girl...
- Relay Therapeutics, Inc.Relay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberRelay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
- Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Generation ADC Pipeline to ClinicSAN DIEGO, September 01, 2026--Styx Biotechnologies, Inc., a San Diego-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors, today announced a strategic agreement with ZoeNCure Therapeutics Pvt. Ltd. to accelerate selected Styx ADC programs toward first-in-human clinical studies.
- aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary SarcoidosisaTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
- iBio, Inc.iBio to Participate in the 2026 Wells Fargo Annual Healthcare ConferenceiBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.
- Cellectis Announces Participation in Upcoming Investor ConferencesCellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences:
- Mark Farrah AssociatesTrends for Health Insurer Profitability as Assessed by Mark Farrah AssociatesPITTSBURGH, September 01, 2026--MFA compared 2025 and 2024, PMPM health premiums and expenses for the Individual, Employer-Group, Medicare, and Medicaid segments.
- HelogenHelogen Announces October Missions to Advance Commercial Manufacturing in Orbit and Establish First Regulatory PathwayLOS ANGELES, September 01, 2026--Helogen, the company building autonomous factories in space for advanced material production, today announced two missions scheduled for October 2026. The missions will support the manufacturing of biomaterials for artificial retinas and orthopedic applications, while advancing the company’s work toward GMP-compliant production and FDA review.
- SBC Medical Group Holdings IncorporatedSBC Medical to Participate in Several Upcoming Investor Conferences in September 2026IRVINE, Calif., September 01, 2026--SBC Medical will be conducting a Non-Deal Roadshow (NDR) and participating in several investor conferences throughout September 2026.
- Jarrow FormulasJarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy and Healthy AgingNew formulas designed to help consumers with proactive long-term health — Jarrow Formulas®, a leading formulator and supplier of science-backed nutritional supplements, today announced the launch of two new products, expanding its...
- Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 — Haier Biomedical (SHA: 688139) showcased a portfolio of automated and digital solutions spanning key pharmaceutical...